KHRNF - Khiron Life Sciences Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.8100
-0.0400 (-4.71%)
At close: 3:39PM EST
Stock chart is not supported by your current browser
Previous Close0.8500
Open0.8265
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.7740 - 0.8431
52 Week Range0.5919 - 3.2800
Volume98,046
Avg. Volume174,397
Market Cap92.679M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3020
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Khiron Increases Clinical Capacity in Colombia by 75% with Opening of Zerenia Integrated Medical Clinic
    CNW Group

    Khiron Increases Clinical Capacity in Colombia by 75% with Opening of Zerenia Integrated Medical Clinic

    Khiron Increases Clinical Capacity in Colombia by 75% with Opening of Zerenia Integrated Medical Clinic

  • Have Insiders Been Buying Khiron Life Sciences Corp. (CVE:KHRN) Shares?
    Simply Wall St.

    Have Insiders Been Buying Khiron Life Sciences Corp. (CVE:KHRN) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

  • PR Newswire

    Khiron CEO Alvaro Torres to Present at AltaCorp/ATB 8th Annual Institutional Investor Conference

    Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced that CEO and Director Alvaro Torres will speak on the International Expansion panel at the AltaCorp/ATB 8th Annual Institutional Investor Conference at 3:10pm on January 14, 2020. Mr. Torres and other members of the Khiron leadership team will also be conducting one-on-one meetings at the conference, taking place January 14-16, 2020 at the Shangri-La Hotel Toronto.

  • CNW Group

    Khiron Welcomes Colombia's Receipt of 2020 Production Quota of 56.5 Tons of High-THC Cannabis

    Khiron Welcomes Colombia's Receipt of 2020 Production Quota of 56.5 Tons of High-THC Cannabis

  • PR Newswire

    Khiron Welcomes Colombia's Receipt of 2020 Production Quota of 56.5 Tons of High-THC Cannabis

    Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, welcomes the Colombian government's announcement that the country has been awarded a record high quota of 21.84% of worldwide high -THC for commercial and scientific purposes. The quota, which is awarded by the International Narcotics Control Board ("INCB"), an independent body for the implementation of the United Nations Drug Convention, affirms Colombia's role as one of the most important supply sources for the licensed global cannabis economy.

  • Benzinga

    Khiron Obtains Good Storage Practices Certification In Peru, Welcomes Cannabis Regulations

    Vertically integrated cannabis company Khiron Life Sciences Corp. (TSXV: KHRN), (OTC: KHRNF) announced Monday that it has obtained Good Storage Practices certification in Peru. The company acknowledged new regulatory guidelines for the medical cannabis program in Peru issued by the country’s Ministry of Health. The regulations lay out the precise steps needed for attaining medical cannabis licenses for import and commercialization.

  • PR Newswire

    Khiron Welcomes Regulatory Guidelines in Peru, Announces Good Storage Practices Certification

    Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today welcomes the release of regulatory guidelines governing the medical cannabis program in Peru, and concurrently, announces its receipt of Good Storage Practices (GSP) certification in the country. Issued by Peru's Ministry of Health earlier this week, the new regulatory guidelines establish clear steps towards securing licenses for the import and commercialization of medical cannabis, for which GSP certification is a crucial prerequisite.

  • Benzinga

    Uruguay Senate Approves New Bill To Regulate Access To Medical Cannabis

    To help put a definitive end to persisting illicit cannabis markets, Uruguay's senate has passed a new bill to regulate medical marijuana. The bill, "A Comprehensive Law for the Promotion and Access to Medical and Therapeutic Cannabis," was introduced into Congress by the "Ir" sector of the “Frente Amplio” party, and approved unanimously. The new bill also presents guidelines for pharmaceutical compounding.

  • CNW Group

    Khiron Welcomes Legalization of Medical Cannabis in Brazil

    Khiron Welcomes Legalization of Medical Cannabis in Brazil

  • CNW Group

    Khiron Announces Chairman Transition and Appointment of Audit Committee Chair

    TORONTO , Nov. 29, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (KHRNF), (Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America , today announced that Sidney Himmel has resigned as Director and Chair of the Board to pursue other interests, effective immediately. "On behalf of my fellow directors, the Company's management team, and shareholders we thank Sid for his many contributions to Khiron since its founding," said Alvaro Torres , Khiron's CEO and Director.

  • We Think Khiron Life Sciences (CVE:KHRN) Needs To Drive Business Growth Carefully
    Simply Wall St.

    We Think Khiron Life Sciences (CVE:KHRN) Needs To Drive Business Growth Carefully

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • CNW Group

    Khiron Announces Option and Restricted Share Unit Grants

    Khiron Announces Option and Restricted Share Unit Grants

  • Benzinga

    Khiron Life Sciences Announces Wider Year-Over-Year Net Loss, Says Cash Position Strong

    Khiron Life Sciences Corp (OTC: KHRNF) (CSE: KHRN) reported third-quarter revenue of CA$2.8 million ($2.1 million) on Tuesday and a CA$47.9 million cash balance. The company announced a net loss for the quarter of CA$10.6 million, or CA$0.09 per share, versus a net loss of CA$5.2 million in the third quarter of 2018.

  • CNW Group

    Khiron Reports Q3 Fiscal 2019 Financial Results, With $47.9 Million Cash Balance and $2.8 Million in Quarterly Revenue

    22 cannabis strains registered in Colombia and in Q3 successfully harvested a number of these strains, converting to an extract. TORONTO , Nov. 26, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN, OTCQB:KHRNF), a cannabis company with core operations in Latin America announced today its financial results for the third quarter ended September 30, 2019 .

  • Market Exclusive

    Khiron Becomes First Colombian Firm to Commercialize THC Cannabis

    Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC) has received approval for commercial production of psychoactive, high-THC cannabis for both domestic and export purposes. The Colombian Technical Quotas Group (TQG) has authorized the company to cultivate and commercialize up to 560 kg or approximately, 65,000 units of psychoactive, high-THC cannabis in 2019. The authorization makes Khiron the first […]The post Khiron Becomes First Colombian Firm to Commercialize THC Cannabis appeared first on Market Exclusive.

  • Benzinga

    Khiron Becomes First Company In Colombia To Obtain Approval To Commercialize High-THC Cannabis

    Vertically integrated company Khiron Life Sciences Corp. (TSXV:KHRN), (OTC: KHRNF) announced Monday it has received authorization to commercialize psychoactive, high-THC cannabis for both domestic and export purposes. Khiron is the first and only cannabis company in Colombia to obtain this approval. The company said this authorization is due to commercial quotas provided to Khiron by the Colombian Technical Quotas Group, which allow the company to grow and commercialize around 65,000 units of psychoactive, high-THC cannabis in 2019, with first commercial cultivation planned to start in the fourth quarter.

  • PR Newswire

    Khiron Receives First Colombian Authorization to Commercialize High-THC Cannabis for Domestic and Export Sales

    Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced that it has become the first and to date, only cannabis company in Colombia authorized to commercialize psychoactive, high-THC cannabis for both domestic and export purposes. Representing a key milestone towards Khiron's stated timeline to bring medical cannabis options to market, the authorization comes as a result of commercial quotas allocated to Khiron by the Colombian Technical Quotas Group ("TQG"), which permit the Company to cultivate and commercialize up to 560 kg – or approximately, 65,000 units – of psychoactive, high-THC cannabis in 2019.